课题基金 / 基金详情

MOLECULAR MECHANISMS OF GROWTH CONTROL AND CARCINOGENESIS

MOLECULAR MECHANISMS OF GROWTH CONTROL AND CARCINOGENESIS
生长控制和致癌的分子机制
批准号:
6289685
负责人:
Jorge Silvio Gutkind
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Jorge Silvio Gutkind的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objective of the project is to explore the molecular basis of cancer, approaching this problem by the study of normal and aberrant functions of molecules that participate in the transduction of proliferative signals. We began demonstrating that mutated genes for certain classes of G proteins are transforming, and that a number of G protein-coupled receptors (GPCRs) behave as potent agonist-dependent oncogenes. Subsequently, we focused on critical molecules conveying mitogenic signals from the cytoplasm to the nucleus, including the family of MAP kinases. Our work led to the discovery of a new biochemical route connecting GPCRs to MAP kinases, involving the activation of Ras by G protein beta gamma. We also demonstrated that GPCRs can stimulate the activity of jun kinase (JNK), a novel enzyme closely related to MAP kinases which phosphorylates the c-jun proto-oncogene product thereby increasing its transcriptional activity. We next found that whereas Ras weakly activates JNK, the small GTP-binding proteins Rac1 and Cdc42 initiate an independent kinase cascade leading to JNK activation, and that Rac and Cdc42 are an integral part of the signaling route, linking many cell surface receptors and naturally occurring human oncogenes to JNK. The emerging picture from these and other studies is that cell surface receptors regulate the activity of parallel kinase cascades which, in turn, control the expression of genetic programs leading to normal or aberrant cell growth. We believe that these findings have helped to identify a number of potential candidates as targets for therapeutic intervention in cancer. - G proteins, Ras, MAP kinases, JNK, Cell cycle control
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Signal Transduction by PI3K/mTOR
Signal Transduction by PI3K/mTOR
Signal Transduction by PI3K/mTOR
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC
海外基金